There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cytokinetics (CYTK – Research Report), Regeneron (REGN – Research Report) and Puma Biotechnology (PBYI – Research Report) with bullish sentiments.
Cytokinetics (CYTK)
H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Cytokinetics today and set a price target of $49.00. The company’s shares closed last Thursday at $39.29.
According to TipRanks.com, Pantginis ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on Cytokinetics is a Strong Buy with an average price target of $59.08, implying a 47.7% upside from current levels. In a report issued on April 21, Mizuho Securities also maintained a Buy rating on the stock with a $80.00 price target.
See the top stocks recommended by analysts >>
Regeneron (REGN)
In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on Regeneron, with a price target of $927.00. The company’s shares closed last Thursday at $753.88.
According to TipRanks.com, Flynn is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Regeneron with a $901.06 average price target, representing a 16.2% upside. In a report issued on April 21, UBS also maintained a Buy rating on the stock with a $926.00 price target.
Puma Biotechnology (PBYI)
In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Puma Biotechnology, with a price target of $8.00. The company’s shares closed last Thursday at $2.61.
According to TipRanks.com, White ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on Puma Biotechnology is a Hold with an average price target of $5.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CYTK:
- Cytokinetics Reports First Quarter 2023 Financial Results
- Is CYTK a Buy, Before Earnings?
- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Cytokinetics to Announce First Quarter Results on May 4, 2023
- Cytokinetics To Participate In The 22nd Annual Needham Virtual Healthcare Conference
